A Phase 1/2, open-label, dose-escalating, multicenter trial (NCT06109181) is evaluating the efficacy to suppress ventricular arrhythmias and the safety of LX2020 in patients with ACM and a mutation in the PKP2 gene. Here, PKP2 is linked to Ventricular arrhythmia.